바로가기  >

Abstract
Background: Despite the widespread use of neoadjuvant chemoradiotherapy, there is no prognostic surrogate marker established in locally advanced rectal cancer.

Objective: This study evaluated the role of neoadjuvant rectal score as a prognostic factor to stratify individual-level risks of survival and tumor recurrence.

Design: This is a retrospective study.

Settings: This study was conducted at the Seoul National University Hospital.

Patients: A total of 397 patients who underwent chemoradiotherapy plus total mesorectal excision were analyzed.

Interventions: There was no intervention.

Main outcome measures: Harrell C statistic and receiver operating characteristic analysis, as well as Cox regression analysis, were used to assess the prognostic strength.

Results: The low (<8), intermediate (8-16), and high (>16) neoadjuvant rectal score groups included 91 (23%), 208 (52%), and 98 patients (25%). A high neoadjuvant rectal score was independently associated with inferior overall survival and disease-free survival (p = 0.011 and 0.008). Regarding the prognostic models adjusted for neoadjuvant rectal score (I) and ypT/N stage (II), the c-index was higher in model I (0.799 and 0.787, p = 0.009 for overall survival; 0.752 and 0.743, p = 0.093 for disease-free survival). The predictive ability of the neoadjuvant rectal score was superior to tumor regression grade, ypT, and ypN in the receiver operating characteristic analyses (p < 0.05 for all). Adjuvant chemotherapy was associated with better overall and disease-free survival (p = 0.003 and 0.052) in the high neoadjuvant rectal score group.

Limitations: Potential selection bias attributed to the retrospective study design was a limitation.

Conclusions: We verified the applicability of the neoadjuvant rectal score to stratify the relapse risk at the individual level for patients with stage II/III rectal cancer undergoing neoadjuvant chemoradiotherapy. Additional studies are needed to validate the usability of neoadjuvant rectal score levels as a determinant of adjuvant strategy. 

Affiliations

Yu Jin Lim  1 , Changhoon Song  2 , Seung Hyuck Jeon  3 , Kyubo Kim  4 , Eui Kyu Chie  3   5
1 Department of Radiation Oncology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea.
2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
3 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
4 Department of Radiation Oncology, Ewha University College of Medicine, Seoul, Republic of Korea.
5 Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.